Evaluation of implementation of evolving practice patterns in the first-line treatment of patients with metastatic non-small cell lung cancer in Turkiye (ESTIMATE): a national, multicenter, retrospective, real-world evidence study
Future Oncology, cilt.21, sa.19, ss.2525-2535, 2025 (SCI-Expanded, Scopus)
- Yayın Türü: Makale / Tam Makale
- Cilt numarası: 21 Sayı: 19
- Basım Tarihi: 2025
- Doi Numarası: 10.1080/14796694.2025.2527477
- Dergi Adı: Future Oncology
- Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, CINAHL, EMBASE, MEDLINE
- Sayfa Sayıları: ss.2525-2535
- Anahtar Kelimeler: Metastatic non-small cell lung cancer, biomarker assessment, treatment patterns, retrospective, real-world evidence, observational study
- Sağlık Bilimleri Üniversitesi Adresli: Evet
Özet
Background: This national, multicenter, retrospective, non-interventional real-world evidence study aimed to address patient characteristics and systemic treatment practices of metastatic non-small cell lung cancer (mNSCLC) patients in Türkiye. Research design and methods: Over 6 months, 636 adults with mNSCLC at 12 Turkish oncology centers provided retrospective data. Results: Adenocarcinoma was the most common histology, with 95% having distant bone metastases and 64.8% having no comorbidities. The most frequently administered first-line therapy was combination chemotherapy followed by targeted therapy and immunotherapy. Overall, 55.5–69.3% of patients were tested for ALK, EGFR, ROS1, and PD-L1. Conclusions: Biomarker screening in mNSCLC patients in Türkiye was suboptimal compared to other countries, especially in public hospitals.